Alexion inks $855M takeover of Wilson Therapeutics | Fierce Biotech
Alexion adds to pipeline rebuild with $855m Wilson buy - PMLiVE
Alexion in €639m bid for Wilson Therapeutics AB - European Biotechnology
ALXN1840 FoCus Phase III Trial in Wilson Disease Met Primary Endpoint Demonstrating Improvement in Copper Mobilisation from Tissues-CliniExpert
UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K ALEXION PHARMACEUTICALS, INC.
Alexion refilling pipeline through potential $1.2bn Syntimmune buy - BioProcess InternationalBioProcess International
Alexion to acquire Wilson Therapeutics for $855 million
Alexion buys Swedish biotech for $855M to broaden rare disease pipeline
Alexion Reports Positive Results from Phase 3 Trial of ALXN1840 in Wilson Disease - Global Genes
WTX101: A Superior Treatment for Wilson Disease
AstraZeneca dumps $855M, near-approval rare disease drug
Alexion Acquires Swedish Treatment for Wilson's Disease
Alexion Pharmaceuticals to acquire Wilson Therapeutics for $855mn
Alexion to Acquire Wilson Therapeutics for $855 Million - Equities News
Alexion to Acquire Wilson Therapeutics | Business Wire
STAT on X: "Alexion Pharmaceuticals said it is buying Sweden's Wilson Therapeutics for $855 million, as the pace of deal-making in the biotech sector ticks higher. https://t.co/2dxJBMUvrX https://t.co/HOBUUk7HJK" / X
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 1) (NASDAQ:ALXN) | Seeking Alpha
Wilson Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alexion Acquires Swedish Treatment for Wilson's Disease
Alexion on X: "Patients living with Wilson disease can develop a wide range of symptoms, including liver disease and/or psychiatric or neurological symptoms. For further advice and support: https://t.co/nrPzQ4A3F4 #WilsonDiseaseAwarenessMonth https://t ...
Drug Candidate for Wilson Disease Meets Primary Endpoint in Phase III Trial | BioSpace
ex995wtxofferstatement
Alexion's Wilson Therapeutics Deal Beats Its Synageva Distaster - Bloomberg
Chantel Wilson Chase | SpeakerHub
Alexion Purchases Wilson Therapeutics for $855M: Expands Pipeline | BioSpace
Alexion's drug meets primary goal in Phase III Wilson disease trial
